Home » Medical Devices » mRNA Vaccine and Therapeutics Market

mRNA Vaccine and Therapeutics Market By Type (Prophylactic, Therapeutic); By End-Use (Hospitals & Clinics, Research Organizations, Others); By Application (Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: mRNA Vaccine and Therapeutics Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-10-30
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: mRNA Vaccine and Therapeutics Market

Summary
Table Of Content
Request Free Sample

Market Overview:

The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800.00 million in 2018 to USD 13,444.94 million in 2024 and is anticipated to reach USD 46,668.48 million by 2032, at a CAGR of 16.93% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
mRNA Vaccine and Therapeutics Market Size 2024	USD 13,444.94 Million
mRNA Vaccine and Therapeutics Market, CAGR	16.93%
mRNA Vaccine and Therapeutics Market Size 2032	USD 46,668.48 Million

The market growth is driven by the rising prevalence of infectious and chronic diseases, advancements in genetic research, and growing investments in biotechnology. Increasing demand for precision medicine and personalized treatments has accelerated mRNA-based therapeutic development. Rapid approvals of COVID-19 vaccines have also boosted confidence in mRNA platforms, encouraging pharmaceutical firms to expand research into cancer immunotherapy, rare genetic disorders, and autoimmune diseases.

North America leads the Global mRNA Vaccine and Therapeutics Market due to strong R&D infrastructure, robust funding, and the presence of major biotech players. Europe follows with supportive regulatory frameworks and a focus on next-generation vaccine development. The Asia-Pacific region is emerging rapidly, supported by government initiatives, expanding healthcare access, and increasing biotech investments, especially in countries like China, Japan, and India.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights:

The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800 million in 2018, reached USD 13,444.94 million in 2024, and is projected to attain USD 46,668.48 million by 2032, growing at a CAGR of 16.93%.
North America held the largest share at 39.8%, supported by strong biotechnology infrastructure and the presence of key players. Europe followed with 21.3%, driven by supportive regulatory systems, while Asia Pacific captured 26.5% due to expanding vaccine research and healthcare modernization.
Asia Pacific emerged as the fastest-growing region, fueled by government funding, local mRNA research, and increased healthcare investments in countries such as China, Japan, and India.
In 2024, hospitals and clinics accounted for around 47% of the end-use segment, supported by large-scale vaccination programs and clinical integration of mRNA therapies.
Research organizations held nearly 35% share, reflecting strong academic collaboration and growing investment in mRNA-based oncology and infectious disease studies.

Global mRNA Vaccine and Therapeutics Market Size

Market Drivers:

Growing Application of mRNA in Infectious and Chronic Disease Treatment

The Global mRNA Vaccine and Therapeutics Market is witnessing rapid expansion due to its broad applications in infectious and chronic disease management. Pharmaceutical companies are actively developing mRNA-based solutions for conditions like influenza, HIV, and cancer. mRNA platforms allow faster production timelines, reducing dependency on traditional vaccine models. Strong pipeline products and successful clinical trials are improving investor confidence. The growing awareness of personalized medicine is creating new treatment pathways. Technological progress in lipid nanoparticles is improving delivery efficiency. It is transforming therapeutic outcomes and expanding treatment accessibility globally. Rising healthcare investments continue to strengthen research and innovation in this field.

For instance, Moderna’s mRNA-1083 influenza vaccine achieved a higher antibody response in over 8,000 Phase 3 trial participants compared to standard flu vaccines, as published in June 2024 results.

Technological Innovations Enhancing Drug Delivery Efficiency and Stability

Continuous technological innovation is a major driver in the Global mRNA Vaccine and Therapeutics Market. Advances in lipid nanoparticle carriers and encapsulation methods have improved mRNA stability and bioavailability. Research in cold-chain management and thermostable formulations is making vaccines more practical for large-scale distribution. Strong collaboration between biotech firms and research institutions is accelerating development. The integration of AI and computational biology is improving sequence design and reducing time to market. It is enabling precise targeting of cells for enhanced therapeutic outcomes. Governments and private investors are supporting innovation through funding and policy backing. These developments are ensuring the reliability and scalability of mRNA-based therapies.

For instance, research published in a March 2023 peer-reviewed journal demonstrated that optimally lyophilized (freeze-dried) mRNA lipid nanoparticles (LNPs) could maintain their transfection efficiency when stored at room temperature (22°C) for at least 12 weeks (three months), offering a potential solution to the cold-chain limitation of existing liquid mRNA vaccines. This study, while promising, was a general academic research effort and did not specifically confirm a BioNTech product has this shelf life.

Growing Investment and Funding from Public and Private Sectors

The market is benefiting from strong financial support across global economies. Major funding initiatives from governments and private investors are fueling mRNA research and commercialization. It is helping companies expand manufacturing capabilities and clinical infrastructure. Pharmaceutical giants are entering strategic alliances to strengthen product portfolios. Academic institutions are also contributing to research diversity through collaborative studies. The increased capital flow ensures faster transition from laboratory discoveries to market-ready therapies. This support is driving long-term sustainability and encouraging smaller biotech startups to innovate. The trend highlights growing confidence in the mRNA platform’s therapeutic potential.

Expanding Scope in Oncology and Rare Disease Therapeutics

Oncology and rare disease treatments are emerging as pivotal areas for mRNA innovation. Researchers are exploring mRNA-based cancer vaccines to trigger immune responses against tumor cells. Personalized vaccines targeting specific tumor mutations are gaining attention. It is creating opportunities for precision medicine and immune-modulating therapies. Rare genetic disorders are also being targeted using mRNA technologies. The ability to code specific proteins helps treat enzyme deficiencies and metabolic conditions. Strong patent activity and collaborations are supporting drug development pipelines. These advancements are expanding the therapeutic scope and improving long-term market resilience.

Market Trends:

Adoption of Personalized and Precision Medicine Approaches in Healthcare Systems

The Global mRNA Vaccine and Therapeutics Market is evolving toward personalized medicine, focusing on patient-specific treatment solutions. Healthcare systems are integrating genomic data and AI-driven tools for therapy customization. It is helping clinicians design targeted therapies with fewer side effects. Pharmaceutical companies are expanding genetic profiling programs to optimize vaccine efficiency. This trend aligns with the shift toward precision-based medical practices. Hospitals and research labs are adopting genomic databases for real-time diagnosis. The growing patient demand for effective and faster treatments is strengthening this transition. It is positioning mRNA therapeutics as a leading tool for personalized healthcare solutions.

For instance, Gritstone Bio’s April 2024 presentation at the AACR Annual Meeting showcased that improvements to its proprietary AI-driven EDGE™ platform resulted in a field-leading HLA Class I prediction accuracy of over 80%. This was an internal R&D achievement and not the result of a 2024 partnership with CureVac, which has its own separate collaborations for neoantigen identification.

Rising Collaborations Between Biotech Firms and Pharmaceutical Companies

Strategic collaborations are shaping innovation in the Global mRNA Vaccine and Therapeutics Market. Partnerships between biotech and pharmaceutical firms are accelerating drug development and clinical validation. Co-development models are reducing time and cost barriers in vaccine production. Governments are supporting public-private collaborations to scale R&D infrastructure. It is helping companies overcome technical challenges and improve global access. Mergers and acquisitions are expanding market reach and portfolio diversity. The collaboration trend is fostering shared knowledge and technical expertise. It is enhancing innovation pipelines and promoting cross-border research integration.

For instance, Sanofi and BioNTech’s existing collaboration for cancer immunotherapies, which began in November 2015 and was expanded in January 2019, successfully moved their first candidate from concept to clinical stage in “well under three years”. Separately, in May 2024, Sanofi announced a new licensing agreement with Novavax for a protein-based flu-COVID combination vaccine, a strategy that moves away from mRNA technology for their influenza portfolio.

Increasing Focus on Non-Vaccine Therapeutic Applications

The market is shifting focus beyond vaccines toward therapeutic use cases such as oncology and regenerative medicine. The Global mRNA Vaccine and Therapeutics Market is exploring mRNA’s role in protein replacement and immune modulation. It is offering new possibilities for genetic and autoimmune disorders. Research into mRNA therapies for cardiovascular and metabolic diseases is expanding. The trend highlights the potential to replace traditional biologics with faster, scalable alternatives. Biotech companies are investing in long-term platforms for multi-disease targeting. Continuous advancements in mRNA design and delivery are improving therapeutic precision. This transition is redefining the future of biopharmaceutical innovation.

Growing Demand for Scalable Manufacturing and Supply Chain Modernization

The expansion of mRNA production capacity is a key trend driving global competitiveness. The Global mRNA Vaccine and Therapeutics Market is experiencing strong investment in modular and automated manufacturing facilities. It is addressing scalability issues faced during pandemic responses. Companies are integrating robotics and AI to optimize yield and quality control. Governments are supporting domestic production to reduce import reliance. Global supply chain networks are adapting to cold-chain requirements with advanced logistics. The modernization of manufacturing systems ensures rapid response capability for emerging health threats. It is building resilience and long-term efficiency in biopharmaceutical production.

Market Challenges Analysis:

Regulatory Complexity and Standardization Issues Across Global Regions

The Global mRNA Vaccine and Therapeutics Market faces complex regulatory frameworks that slow product approvals. Differences in national guidelines for genetic materials, clinical testing, and quality control create inconsistency. Regulatory harmonization remains limited, leading to delays in commercialization. It is challenging for small and mid-sized companies to meet stringent safety and efficacy standards. High compliance costs add further burden to development timelines. The rapid pace of mRNA innovation often outpaces existing regulatory frameworks. Limited awareness among regulators regarding emerging mRNA technologies increases review times. Coordinated international efforts are needed to simplify approval pathways and promote transparency.

Manufacturing Costs, Cold Chain Constraints, and Workforce Shortages

Manufacturing complexity continues to challenge the scalability of mRNA products. The Global mRNA Vaccine and Therapeutics Market is dealing with high costs for specialized equipment, raw materials, and temperature-controlled logistics. Cold-chain infrastructure gaps restrict global distribution, especially in low-income nations. Skilled workforce shortages in molecular biology and RNA engineering further limit capacity expansion. It is difficult for emerging companies to maintain cost efficiency while ensuring quality. Energy-intensive production processes contribute to operational challenges. The need for automation and process optimization is becoming critical. Addressing these limitations will determine the market’s long-term growth and accessibility.

Market Opportunities:

Expansion into Cancer Immunotherapy and Genetic Disorder Treatments

The Global mRNA Vaccine and Therapeutics Market offers major opportunities in oncology and genetic medicine. The flexibility of mRNA enables rapid design of tumor-specific vaccines, improving patient response rates. It is also opening potential in treating genetic deficiencies through protein synthesis. Advances in lipid nanoparticles and vector design are improving delivery success in complex tissues. Collaborations between biotech firms and cancer research institutes are growing. These factors are enhancing the clinical pipeline for next-generation therapeutics. The expanding role of mRNA platforms is likely to reshape precision treatment landscapes worldwide.

Rising Government Support and Global Health Preparedness Initiatives

Governments and health organizations are prioritizing mRNA technologies for future pandemic readiness. The Global mRNA Vaccine and Therapeutics Market is gaining policy-driven momentum through funding and capacity-building programs. It is attracting public-private partnerships aimed at expanding regional production hubs. National strategies promoting local manufacturing and research autonomy are accelerating adoption. The focus on self-reliance and resilient healthcare systems is creating strong growth prospects. Public investment in cold-chain infrastructure and technology transfer initiatives is improving global accessibility. These developments are fostering innovation, preparedness, and equitable health outcomes.

Global mRNA Vaccine and Therapeutics Market Seg

Market Segmentation Analysis:

By Type

The Global mRNA Vaccine and Therapeutics Market is divided into prophylactic and therapeutic segments. Prophylactic mRNA vaccines hold a dominant share due to their successful use in preventing infectious diseases such as COVID-19 and influenza. Continuous innovation in vaccine delivery platforms supports their sustained demand. The therapeutic segment is gaining traction with growing research in cancer immunotherapy, rare genetic disorders, and metabolic diseases. It benefits from the ability of mRNA technology to encode specific proteins for targeted therapy. The shift toward chronic disease management is accelerating investment in therapeutic applications.

For instance, Sanofi and Translate Bio’s mRNA therapy for cystic fibrosis (MRT5005) demonstrated robust dose-dependent delivery and expression of human CFTR mRNA and protein in animal studies (specifically rats and nonhuman primates), with mRNA levels in the lungs increasing up to 1500-fold compared to endogenous levels.

By End-Use

Hospitals and clinics lead the end-use segment owing to their role in vaccination programs and advanced treatment delivery. Strong healthcare infrastructure and expanding immunization coverage drive their dominance. Research organizations follow closely, supported by active R&D funding and academic collaborations. It is fostering breakthroughs in personalized and precision medicine. The “Others” category, including contract manufacturing and biotech startups, is emerging through specialized drug development initiatives.

By Application

Infectious diseases represent the largest application segment, supported by rising global health challenges and preventive immunization campaigns. Oncology is emerging rapidly as mRNA-based cancer vaccines enter clinical pipelines. Rare genetic diseases and respiratory disorders also show promising potential due to ongoing advancements in targeted gene therapy. The “Others” segment covers autoimmune and cardiovascular conditions, reflecting the broadening therapeutic potential of mRNA technology. It highlights the adaptability of this platform across multiple medical domains.

Global mRNA Vaccine and Therapeutics Market Seg1

Segmentation:

By Type

Prophylactic
Therapeutic

By End-Use

Hospitals & Clinics
Research Organizations
Others

By Application

Infectious Diseases
Oncology
Rare Genetic Diseases
Respiratory Diseases
Others

By Region

North America
- S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East
- GCC Countries
- Israel
- Turkey
- Rest of Middle East
Africa
- South Africa
- Egypt
- Rest of Africa

Regional Analysis:

North America

The North America Global mRNA Vaccine and Therapeutics Market size was valued at USD 3,137.94 million in 2018 to USD 5,349.66 million in 2024 and is anticipated to reach USD 18,546.14 million by 2032, at a CAGR of 16.9% during the forecast period. North America dominates the global market, accounting for the largest share due to advanced healthcare infrastructure, robust biotechnology R&D, and high adoption of novel therapeutics. It benefits from strong government funding, well-established clinical trial networks, and the presence of key players such as Moderna and Pfizer. Continuous product innovation and collaboration between pharmaceutical and academic institutions are accelerating research in cancer and infectious disease applications. Favorable regulatory frameworks and rapid approval mechanisms strengthen market penetration. The region’s emphasis on vaccine manufacturing and innovation leadership supports sustained growth in the coming years.

Europe

The Europe Global mRNA Vaccine and Therapeutics Market size was valued at USD 1,739.40 million in 2018 to USD 2,860.72 million in 2024 and is anticipated to reach USD 9,275.49 million by 2032, at a CAGR of 15.9% during the forecast period. Europe holds a substantial market share due to active participation of companies such as BioNTech and CureVac. It benefits from strong research institutions and supportive regulatory bodies like the EMA promoting biotechnology advancements. Public-private collaborations are driving vaccine development and cancer immunotherapy research. Countries such as Germany, the UK, and France are key contributors to regional growth. It is also witnessing rising investment in precision medicine and biomanufacturing. The focus on developing regional supply chains and sustainable healthcare strategies reinforces its leadership in biotechnology innovation.

Asia Pacific

The Asia Pacific Global mRNA Vaccine and Therapeutics Market size was valued at USD 1,981.20 million in 2018 to USD 3,560.84 million in 2024 and is anticipated to reach USD 13,594.57 million by 2032, at a CAGR of 18.3% during the forecast period. Asia Pacific represents the fastest-growing regional market, driven by expanding healthcare infrastructure, government funding, and local manufacturing capacity. Countries such as China, Japan, and India are investing heavily in biotechnology and vaccine development. Growing awareness of preventive healthcare and rising chronic disease prevalence support mRNA adoption. The region’s cost-effective clinical trials and supportive regulatory frameworks encourage multinational companies to establish partnerships. It is emerging as a vital hub for clinical research, vaccine innovation, and large-scale production. Rapid technological advancement and favorable demographic factors will continue to boost regional expansion.

Latin America

The Latin America Global mRNA Vaccine and Therapeutics Market size was valued at USD 553.80 million in 2018 to USD 946.39 million in 2024 and is anticipated to reach USD 3,074.05 million by 2032, at a CAGR of 16.0% during the forecast period. Latin America is gradually expanding its market presence through public health initiatives and vaccination programs. Brazil and Mexico are key markets, supported by investments in biotechnology and clinical research. The growing burden of infectious diseases and government-led healthcare reforms are creating favorable conditions for adoption. It is also benefiting from regional collaborations with global pharmaceutical players for vaccine distribution. Improvements in healthcare access and diagnostic capabilities are strengthening demand for innovative therapies. Latin America’s young population and increasing R&D spending position it as an emerging growth region.

Middle East

The Middle East Global mRNA Vaccine and Therapeutics Market size was valued at USD 241.80 million in 2018 to USD 384.44 million in 2024 and is anticipated to reach USD 1,171.64 million by 2032, at a CAGR of 15.1% during the forecast period. The region’s market is expanding due to increasing healthcare modernization and growing investments in life sciences. GCC countries are leading growth with strategic national vaccination programs and biomedical research investments. It is witnessing partnerships with global biotech firms to develop regional manufacturing capacity. Government initiatives supporting local production and R&D diversification are fueling development. The rising prevalence of chronic diseases and rising awareness of preventive healthcare are driving market uptake. Continuous improvements in logistics and cold-chain infrastructure are enhancing accessibility to mRNA-based products.

Africa

The Africa Global mRNA Vaccine and Therapeutics Market size was valued at USD 145.86 million in 2018 to USD 342.90 million in 2024 and is anticipated to reach USD 1,006.60 million by 2032, at a CAGR of 14.0% during the forecast period. Africa’s market share remains smaller but is gaining attention through vaccine equity programs and international partnerships. It is witnessing progress in healthcare infrastructure and biotechnology education. Countries such as South Africa and Egypt are leading regional efforts in vaccine research and production. Collaborations with WHO and global health organizations are improving access to advanced therapeutics. Growing demand for immunization and disease control initiatives supports gradual market penetration. The region’s increasing investment in local manufacturing capabilities and cold-chain systems enhances readiness for future mRNA deployment.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Moderna Inc.
BioNTech SE
CureVac N.V.
Arcturus Therapeutics
Sanofi
GSK Plc.
Argos Therapeutics Inc.
Ethris
Pfizer Inc.
AstraZeneca

Competitive Analysis:

The Global mRNA Vaccine and Therapeutics Market is highly competitive, driven by innovation, research intensity, and strategic alliances. Leading companies such as Moderna, BioNTech, Pfizer, and CureVac dominate through strong product portfolios and R&D investment. It is characterized by rapid clinical advancements and patent-driven competition across vaccine and therapeutic pipelines. Partnerships with academic institutions and government funding programs strengthen their research base. Smaller biotech firms are entering the market with niche products targeting cancer and rare genetic disorders. Companies focus on expanding global manufacturing capacity and distribution networks. Continuous improvements in lipid nanoparticles and formulation technologies enhance product differentiation and long-term competitiveness.

Recent Developments:

In October 2025, Moderna Inc. officially announced discontinuation of development for its investigational CMV vaccine, mRNA-1647, after the pivotal Phase 3 trial did not meet the efficacy endpoint, marking a setback for one of their key late-stage pipeline assets.
In October 2025, BioNTech SE continued integrating advanced artificial intelligence into its mRNA discovery pipeline, co-hosting its second AI Day event in London together with InstaDeep Ltd., to showcase AI applications across vaccine and therapeutics development.
In June–October 2025, CureVac N.V. entered into a binding agreement to be acquired by BioNTech SE for $1.25 billion, strengthening BioNTech’s mRNA cancer immunotherapy portfolio.

Report Coverage:

The research report offers an in-depth analysis based on type, end-use, and application segments. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Continued investment in mRNA technology will expand vaccine and therapeutic pipelines.
Cancer immunotherapy is expected to emerge as a key growth driver.
Regional manufacturing hubs will strengthen supply chain resilience.
AI and bioinformatics will improve mRNA design and sequence optimization.
Partnerships between pharma and biotech firms will increase innovation speed.
Advancements in lipid nanoparticles will improve delivery efficiency.
Demand for mRNA-based treatments in rare diseases will grow steadily.
Regulatory harmonization will enhance approval timelines globally.
Expansion into non-vaccine applications will diversify revenue sources.
Public and private funding will sustain long-term R&D activities.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 :mRNA THERAPEUTICS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview

3.2 Catalysts of Expansion – Key Market Drivers

3.2.1 Momentum Boosters – Growth Triggers

3.2.2 Innovation Fuel – Disruptive Technologies

3.3 Headwinds & Crosswinds – Market Restraints

3.3.1 Regulatory Tides – Compliance Challenges

3.3.2 Economic Frictions – Inflationary Pressures

3.4 Untapped Horizons – Growth Potential & Opportunities

3.5 Strategic Navigation – Industry Frameworks

3.5.1 Market Equilibrium – Porter’s Five Forces

3.5.2 Ecosystem Dynamics – Value Chain Analysis

3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend

3.6.2 Price Trend by product

CHAPTER NO. 4 :KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Type Frontiers – Lucrative Type Categories

4.3 End-use Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Type & End-use Revenue

CHAPTER NO. 6 :TRADE & COMMERCE ANALYSIS

6.1.Import Analysis by Region

6.1.1. Global mRNA Therapeutics Market Import Revenue By Region

6.2.Export Analysis by Region

6.2.1. Global mRNA Therapeutics Market Export Revenue By Region

CHAPTER NO. 7 :COMPETITION ANALYSIS

7.1.Company Market Share Analysis

7.1.1. Global mRNA Therapeutics Market: Company Market Share

7.2. Global mRNA Therapeutics Market Company Revenue Market Share

7.3.Strategic Developments

7.3.1.Acquisitions & Mergers

7.3.2. New Type Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 :mRNA THERAPEUTICS MARKET – BY TYPE SEGMENT ANALYSIS

8.1.mRNA Therapeutics Market Overview by Type Segment

8.1.1. mRNA Therapeutics Market Revenue Share By Type

8.2. Prophylactic

8.3. Therapeutic

CHAPTER NO. 9 : mRNA THERAPEUTICS MARKET – BY END-USE SEGMENT ANALYSIS

9.1.mRNA Therapeutics Market Overview by End-use Segment

9.1.1. mRNA Therapeutics Market Revenue Share By End-use

9.2. Hospitals & Clinics

9.3. Research Organizations

9.4. Others

CHAPTER NO. 10 : mRNA THERAPEUTICS MARKET – BY APPLICATION SEGMENT ANALYSIS

10.1.mRNA Therapeutics Market Overview by Application Segment

10.1.1. mRNA Therapeutics Market Revenue Share By Application

10.2. Infectious Diseases

10.3. Oncology

10.4. Rare Genetic Diseases

10.5. Respiratory Diseases

10.6. Others

CHAPTER NO. 11 :mRNA THERAPEUTICS MARKET – REGIONAL ANALYSIS

11.1.mRNA Therapeutics Market Overview by Region Segment

11.1.1. Global mRNA Therapeutics Market Revenue Share By Region

11.1.3.Regions

11.1.4.Global mRNA Therapeutics Market Revenue By Region

.1.6.Type

11.1.7.Global mRNA Therapeutics Market Revenue By Type

11.1.9.End-use

11.1.10. Global mRNA Therapeutics Market Revenue By End-use

11.1.12.Application

11.1.13. Global mRNA Therapeutics Market Revenue By Application

CHAPTER NO. 12 : NORTH AMERICA mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

12.1.North America mRNA Therapeutics Market Overview by Country Segment

12.1.1.North America mRNA Therapeutics Market Revenue Share By Region

12.2.North America

12.2.1.North America mRNA Therapeutics Market Revenue By Country

12.2.2.Type

12.2.3.North America mRNA Therapeutics Market Revenue By Type

12.2.4.End-use

12.2.5.North America mRNA Therapeutics Market Revenue By End-use

2.2.6.Application

12.2.7.North America mRNA Therapeutics Market Revenue By Application

2.3.U.S.

12.4.Canada

12.5.Mexico

CHAPTER NO. 13 :EUROPE mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

13.1. Europe mRNA Therapeutics Market Overview by Country Segment

13.1.1. Europe mRNA Therapeutics Market Revenue Share By Region

13.2.Europe

13.2.1.Europe mRNA Therapeutics Market Revenue By Country

13.2.2.Type

13.2.3.Europe mRNA Therapeutics Market Revenue By Type

13.2.4.End-use

13.2.5. Europe mRNA Therapeutics Market Revenue By End-use

13.2.6.Application

13.2.7. Europe mRNA Therapeutics Market Revenue By Application

13.3.UK

13.4.France

13.5.Germany

13.6.Italy

13.7.Spain

13.8.Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

14.1.Asia Pacific mRNA Therapeutics Market Overview by Country Segment

14.1.1.Asia Pacific mRNA Therapeutics Market Revenue Share By Region

14.2.Asia Pacific

14.2.1. Asia Pacific mRNA Therapeutics Market Revenue By Country

14.2.2.Type

14.2.3.Asia Pacific mRNA Therapeutics Market Revenue By Type

14.2.4.End-use

14.2.5.Asia Pacific mRNA Therapeutics Market Revenue By End-use

14.2.5.Application

14.2.7.Asia Pacific mRNA Therapeutics Market Revenue By Application

14.3.China

14.4.Japan

14.5.South Korea

14.6.India

14.7.Australia

14.8.Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

15.1.Latin America mRNA Therapeutics Market Overview by Country Segment

15.1.1.Latin America mRNA Therapeutics Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America mRNA Therapeutics Market Revenue By Country

15.2.2.Type

15.2.3. Latin America mRNA Therapeutics Market Revenue By Type

15.2.4.End-use

15.2.5.Latin America mRNA Therapeutics Market Revenue By End-use

15.2.6.Application

15.2.7.Latin America mRNA Therapeutics Market Revenue By Application

15.3.Brazil

15.4.Argentina

15.5.Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

16.1.Middle East mRNA Therapeutics Market Overview by Country Segment

16.1.1.Middle East mRNA Therapeutics Market Revenue Share By Region

16.2.Middle East

16.2.1. Middle East mRNA Therapeutics Market Revenue By Country

16.2.2.Type

16.2.3.Middle East mRNA Therapeutics Market Revenue By Type

16.2.4.End-use

16.2.5.Middle East mRNA Therapeutics Market Revenue By End-use

16.2.6. Application

16.2.7.Middle East mRNA Therapeutics Market Revenue By Application

16.3.GCC Countries

16.4. Israel

16.5. Turkey

16.6.Rest of Middle East

CHAPTER NO. 17 :AFRICA mRNA THERAPEUTICS MARKET – COUNTRY ANALYSIS

17.1. Africa mRNA Therapeutics Market Overview by Country Segment

17.1.1.Africa mRNA Therapeutics Market Revenue Share By Region

17.2. Africa

17.2.1.Africa mRNA Therapeutics Market Revenue By Country

17.2.2.Type

17.2.3.Africa mRNA Therapeutics Market Revenue By Type

17.2.4.End-use

17.2.5. Africa mRNA Therapeutics Market Revenue By End-use

17.2.6.Application

17.2.7. Africa mRNA Therapeutics Market Revenue By Application

17.3. South Africa

17.4.Egypt

17.5.Rest of Africa

CHAPTER NO. 18 :COMPANY PROFILES

18.1. Moderna Inc.

18.1.1.Company Overview

18.1.2.Type Portfolio

18.1.3.Financial Overview

18.1.4.Recent Developments

18.1.5.Growth Strategy

18.1.6.SWOT Analysis

18.2. BioNTech SE

18.3. CureVac N.V.

18.4. Arcturus Therapeutics

18.5. Sanofi

18.6. GSK Plc.

18.7. Argos Therapeutics Inc.

18.8. Ethris

18.9. Pfizer Inc.

18.10. AstraZeneca

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently asked questions

What is the current market size for Global mRNA Vaccine and Therapeutics Market, and what is its projected size in 2032?

The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800 million in 2018 and reached USD 13,444.94 million in 2024. It is anticipated to attain USD 46,668.48 million by 2032, reflecting strong long-term growth potential.

At what Compound Annual Growth Rate is the Global mRNA Vaccine and Therapeutics Market projected to grow between 2025 and 2032?

The market is projected to grow at a CAGR of 16.93% during the forecast period. The rising adoption of mRNA-based therapies and continuous innovation in vaccine platforms are driving this growth rate.

Which Global mRNA Vaccine and Therapeutics Market segment held the largest share in 2024?

The prophylactic segment held the largest share in 2024 due to widespread demand for mRNA vaccines against infectious diseases, supported by strong public immunization initiatives and pharmaceutical investment.

What are the primary factors fueling the growth of the Global mRNA Vaccine and Therapeutics Market?

Key growth factors include increased focus on infectious disease prevention, rapid R&D advancements, supportive regulatory policies, and expansion of personalized medicine. Growing funding for biopharmaceutical innovation is further strengthening growth.

Who are the leading companies in the Global mRNA Vaccine and Therapeutics Market?

Major players include Moderna Inc., BioNTech SE, Pfizer Inc., CureVac N.V., and GSK Plc. These companies are leading innovation through product development, strategic collaborations, and global manufacturing expansion.

Which region commanded the largest share of the Global mRNA Vaccine and Therapeutics Market in 2024?

North America commanded the largest share in 2024, supported by advanced research infrastructure, strong government funding, and the presence of major biotechnology firms driving innovation and commercialization.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Medical Tapes and Bandages Market

The Medical Tapes and Bandages Market size was valued at USD 8.08 Billion in 2024 and is anticipated to reach USD 11.76 Billion by 2032, at a CAGR of 4.8% during the forecast period.

Voice Prosthesis Market

Voice Prosthesis Market size was valued at USD 335.36 million in 2024 and is anticipated to reach USD 546.74 million by 2032, at a CAGR of 6.3% during the forecast period.

Electrodermal Activity Detecting Devices Market

The Electrodermal Activity Detecting Devices Market size was valued at USD 1,020.00 million in 2018 to USD 1,466.88 million in 2024 and is anticipated to reach USD 3,452.45 million by 2032, at a CAGR of 11.39% during the forecast period.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market was valued at USD 357.16 million in 2024 and is anticipated to reach USD 1078.2 million by 2032, growing at a CAGR of 14.81% during the forecast period.

Surgical Generators Market

Surgical Generators market size reached USD 1,788.5 million in 2024 and is projected to grow to USD 3,175.54 million by 2032, recording a CAGR of 7.44% during the forecast period.

Photomedicine Market

The Photomedicine Market was valued at USD 498.14 million in 2024 and is projected to reach USD 702.46 million by 2032, expanding at a CAGR of 4.39% during the forecast period.

Hereditary Testing Market

Hereditary testing market was valued at USD 7.74 billion in 2024 and is anticipated to reach USD 14.12 billion by 2032, growing at a CAGR of 7.8% during the forecast period.

Neonatal Intensive Care Respiratory Devices Market

Neonatal Intensive Care Respiratory Devices market size reached USD 1,760.33 million in 2024 and is projected to grow to USD 2,522.59 million by 2032, registering a CAGR of 4.6% during the forecast period.

Flow Imaging Microscopy Analysis Market

Flow Imaging Microscopy Analysis Market size was valued USD 44.6 million in 2024 and is anticipated to reach USD 77.26 million by 2032, at a CAGR of 7.11% during the forecast period.

Digital Brain Health Market

The Digital Brain Health Market was valued at USD 231,118 million in 2024 and is projected to reach USD 406,401.5 million by 2032, growing at a CAGR of 7.31% during the forecast period.

Enteral Tube Feeding Formula Market

Enteral Tube feeding formula market was valued at USD 7.68 billion in 2024 and is anticipated to reach USD 11.53 billion by 2032, growing at a CAGR of 5.21 % during the forecast period.

Biochip Scanner Market

Biochip Scanner Market size was valued at USD 13.32 Billion in 2024 and is anticipated to reach USD 30.48 Billion by 2032, at a CAGR of 10.9% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample